Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Long

Showing results (101-110 of 108) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 108 results.
Eclinicalmedicine|April 8, 2024
Sustainability and impact of an intervention to improve initiation of tuberculosis preventive treatment: results from a follow-up study of the ACT4 randomized trialDick Menzies, Joseph Obeng, Panji Hadisoemarto, et al.
The Lancet. Public Health|February 11, 2018
Determinants of tuberculosis trends in six Indigenous populations of the USA, Canada, and Greenland from 1960 to 2014: a population-based studyKianoush Dehghani, Zhiyi Lan, Peizhi Li, et al.
Annals of Internal Medicine|June 17, 2020
Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different SettingsMayara Lisboa Bastos, Jonathon R Campbell, Olivia Oxlade, et al.
Journal of Proteome Research|October 13, 2009
Pneumococcal pneumonia: potential for diagnosis through a urinary metabolic profileCarolyn M Slupsky, Kathryn N Rankin, Hao Fu, et al.
The Lancet. Respiratory Medicine|March 29, 2024
High-dose, short-duration versus standard rifampicin for tuberculosis preventive treatment: a partially blinded, three-arm, non-inferiority, randomised, controlled trialRovina Ruslami, Federica Fregonese, Lika Apriani, et al.
The New England Journal of Medicine|August 2, 2018
Safety and Side Effects of Rifampin versus Isoniazid in ChildrenThierno Diallo, Menonli Adjobimey, Rovina Ruslami, et al.
The Lancet. Public Health|March 25, 2021
Effectiveness and cost-effectiveness of a health systems intervention for latent tuberculosis infection management (ACT4): a cluster-randomised trialOlivia Oxlade, Andrea Benedetti, Mênonli Adjobimey, et al.
The New England Journal of Medicine|August 2, 2018
Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in AdultsDick Menzies, Menonli Adjobimey, Rovina Ruslami, et al.
Pageof 11

Showing results (101-110 of 108) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 108 results.
Eclinicalmedicine|April 8, 2024
Sustainability and impact of an intervention to improve initiation of tuberculosis preventive treatment: results from a follow-up study of the ACT4 randomized trialDick Menzies, Joseph Obeng, Panji Hadisoemarto, et al.
The Lancet. Public Health|February 11, 2018
Determinants of tuberculosis trends in six Indigenous populations of the USA, Canada, and Greenland from 1960 to 2014: a population-based studyKianoush Dehghani, Zhiyi Lan, Peizhi Li, et al.
Annals of Internal Medicine|June 17, 2020
Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different SettingsMayara Lisboa Bastos, Jonathon R Campbell, Olivia Oxlade, et al.
Journal of Proteome Research|October 13, 2009
Pneumococcal pneumonia: potential for diagnosis through a urinary metabolic profileCarolyn M Slupsky, Kathryn N Rankin, Hao Fu, et al.
The Lancet. Respiratory Medicine|March 29, 2024
High-dose, short-duration versus standard rifampicin for tuberculosis preventive treatment: a partially blinded, three-arm, non-inferiority, randomised, controlled trialRovina Ruslami, Federica Fregonese, Lika Apriani, et al.
The New England Journal of Medicine|August 2, 2018
Safety and Side Effects of Rifampin versus Isoniazid in ChildrenThierno Diallo, Menonli Adjobimey, Rovina Ruslami, et al.
The Lancet. Public Health|March 25, 2021
Effectiveness and cost-effectiveness of a health systems intervention for latent tuberculosis infection management (ACT4): a cluster-randomised trialOlivia Oxlade, Andrea Benedetti, Mênonli Adjobimey, et al.
The New England Journal of Medicine|August 2, 2018
Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in AdultsDick Menzies, Menonli Adjobimey, Rovina Ruslami, et al.
Pageof 11